Present Status and Problems on Molecular Targeted Therapy of Cancer
Nagahiro Saijo
Cancer Res Treat. 2012;44(1):1-10.   Published online 2012 Mar 31     DOI:
Citations to this article as recorded by Crossref logo
BRCA Mutations and PARP Inhibitors in Breast and/or Ovarian Cancer Patients
Abdulrahim Gari, Ghufran Rawas, Ahmad Mufti, Omima Elemam
International Journal Of Pharmaceutical Research And Allied Sciences.2021; 10(3): 33.     CrossRef
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
Nur Aininie Yusoh, Haslina Ahmad, Martin R. Gill
ChemMedChem.2020; 15(22): 2121.     CrossRef
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
Dan Le, Karen A. Gelmon
Expert Review of Clinical Pharmacology.2018; 11(9): 833.     CrossRef
Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer
Sumi Yun, Yoonjin Kwak, Soo Kyung Nam, An Na Seo, Heung-Kwon Oh, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee
Cancer Research and Treatment.2018; 50(4): 1351.     CrossRef
Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy
Carlo Matera, Alexandre M. J. Gomila, N├║ria Camarero, Michela Libergoli, Concepci├│ Soler, Pau Gorostiza
Journal of the American Chemical Society.2018; 140(46): 15764.     CrossRef
Conceptual frameworks of synthetic lethality in clear cell carcinoma of the ovary (Review)
Hiroshi Kobayashi, Naoki Kawahara, Kenji Ogawa, Yuki Yamada, Kana Iwai, Emiko Niiro, Sachiko Morioka
Biomedical Reports.2018;[Epub]     CrossRef
Discovery of [5-Amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Hirosato Ebiike, Naoki Taka, Masayuki Matsushita, Masayuki Ohmori, Kyoko Takami, Ikumi Hyohdoh, Masami Kohchi, Tadakatsu Hayase, Hiroki Nishii, Kenji Morikami, Yoshito Nakanishi, Nukinori Akiyama, Hidetoshi Shindoh, Nobuya Ishii, Takehito Isobe, Hiroharu
Journal of Medicinal Chemistry.2016; 59(23): 10586.     CrossRef
Highlights for ESMO 40: celebration review for lifetime achievement awards
Nagahiro Saijo
ESMO Open.2016; 1(1): e000010.     CrossRef
Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
Seung Eun Lee, Boram Lee, Mineui Hong, Ji-Young Song, Kyungsoo Jung, Maruja E Lira, Mao Mao, Joungho Han, Jhingook Kim, Yoon-La Choi
Modern Pathology.2015; 28(4): 468.     CrossRef
Metabolic stress induces a Wnt-dependent cancer stem cell-like state transition
E Lee, J Yang, M Ku, N H Kim, Y Park, C B Park, J-S Suh, E S Park, J I Yook, G B Mills, Y-M Huh, J-H Cheong
Cell Death & Disease.2015; 6(7): e1805.     CrossRef
Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT
Martin W Huellner, Timothy D Collen, Philipp Gut, Ralph Winterhalder, Chantal Pauli, Joachim Diebold, Burkhardt Seifert, Klaus Strobel, Patrick Veit-Haibach
EJNMMI Research.2014; 4(1): 6.     CrossRef
PARP inhibition and synthetic lethality in ovarian cancer
Ramez N Eskander, Krishnansu S Tewari
Expert Review of Clinical Pharmacology.2014; 7(5): 613.     CrossRef
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer
Ramez N. Eskander, Krishnansu S. Tewari
Journal of Gynecologic Oncology.2014; 25(3): 249.     CrossRef
Influence of Ribosomal Protein L39-L in the Drug Resistance Mechanisms of Lacrimal Gland Adenoid Cystic Carcinoma Cells
Qing Ye, Shao-Feng Ding, Zhi-An Wang, Jie Feng, Wen-Bin Tan
Asian Pacific Journal of Cancer Prevention.2014; 15(12): 4995.     CrossRef
Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim
Cancer Research and Treatment.2013; 45(2): 79.     CrossRef
Personalized Oncology in Interventional Radiology
Nadine Abi-Jaoudeh, Austin G. Duffy, Tim F. Greten, Elise C. Kohn, Timothy W.I. Clark, Bradford J. Wood
Journal of Vascular and Interventional Radiology.2013; 24(8): 1083.     CrossRef
Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells
Mei Wang, Zi Min Liu, Xiang Chun Li, Yi Tang Yao, Zong Xiu Yin
Journal of Chemotherapy.2013; 25(3): 162.     CrossRef
Interleukin 24: Mechanisms and therapeutic potential of an anti-cancer gene
Erin L. Whitaker, Valery A. Filippov, Penelope J. Duerksen-Hughes
Cytokine & Growth Factor Reviews.2012; 23(6): 323.     CrossRef
Personalized Medicine
K.S. Kornman, G.W. Duff
Journal of Dental Research.2012; 91(7_suppl): S8.     CrossRef